Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER+ / HER2- Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07085767
What this trial is testing

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 1,000
Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Early research (Phase 1)Active Not RecruitingNCT05870579
What this trial is testing

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 28
Early research (Phase 1)Ended earlyNCT03596658
What this trial is testing

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
ER+ HER2- Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 4
Testing effectiveness (Phase 2)Study completedNCT01160718
What this trial is testing

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Swiss Cancer Institute 46
Large-scale testing (Phase 3)Looking for participantsNCT06757634
What this trial is testing

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Who this might be right for
Breast Cancer
Celcuity Inc 1,180
Testing effectiveness (Phase 2)Looking for participantsNCT06064812
What this trial is testing

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer Stage IV+1 more
Forward Pharmaceuticals Co., Ltd. 99
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Large-scale testing (Phase 3)Looking for participantsNCT07647328
What this trial is testing

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 150
Early research (Phase 1)Study completedNCT02248090
What this trial is testing

AZD9496 First Time in Patients Ascending Dose Study

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 45
Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Testing effectiveness (Phase 2)Study completedNCT02007512
What this trial is testing

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 247
Testing effectiveness (Phase 2)Study completedNCT02756364
What this trial is testing

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Who this might be right for
Breast Neoplasms
Calithera Biosciences, Inc 141
Testing effectiveness (Phase 2)Study completedNCT00856492
What this trial is testing

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 215
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Not applicableUnknownNCT06544577
What this trial is testing

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Who this might be right for
ESR1 Gene MutationAdvanced Breast CancerSafety
SciClone Pharmaceuticals 350
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Next Page